The Bcl‑2 inhibitors market centers on drugs that block the Bcl‑2 protein, a key regulator that helps cancer cells avoid programmed cell death (apoptosis). By inhibiting Bcl‑2, these therapies push malignant cells toward apoptosis, making them especially valuable in hematologic cancers where Bcl‑2 overexpression is common.
The market was estimated at about USD 4.52 billion in 2023 and is...
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek